GPR75-Targeted Drug Discovery Services

Introduction

GPR75 is a member of the G protein-coupled receptor family. It is encoded by the GPR75 gene located on chromosome 2. GPRs are cell surface receptors that activate guanine-nucleotide binding proteins upon the binding of a ligand.[supplied by OMIM, Jul 2002] It has been found that GPR75 is expressed in brain, heart, kidney, and other tissues which participate in blood pressure control and have the ability to produce 20-HETE. Nowadays, GPR75 has been identified as the 20-HETE receptor. It is able to bind 20-HETE with high affinity and activates a signaling cascade in order to exert various functions of 20-HETE, such as hypertension, vascular dysfunction and remodeling.

Direction of Drugs Discovery

• Developing New Clinical Effects on GPR75 from Existing Drugs

Drugs

To be updated

What We Offer

Target Testing

CD BioSciences provides GPR75 testing services by WB, IF, ICC, or IHC assay. The results of GPR75 testing are used to evaluate the activities of candidates against GPR75 or targeted diseases. You can choose one or more testing ways to detect the level of GPR75 according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• GPR75-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on GPR75-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Doyne honeycomb retinal dystrophy.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted GPR75. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718904.
4. Garcia, V., et al., 20-hete signals through g-protein-coupled receptor gpr75 (g(q)) to affect vascular function and trigger hypertension. Circ Res, 2017. 120(11): p. 1776-1788.